Community
Company
News
Contact Us
Sign in

Please select the option that best describes you:

Topics: Rheumatology • Spondyloarthritis

What is your experience with using oral roflumilast for psoriatic arthritis?

Related Questions

What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?

Do you utilize serial MRI imaging in patients with axial spondyloarthritis to ensure good disease control or do you rely on symptoms and physical exam to assess treatment response?

Do you generally attempt to taper and discontinue biologics in a patient with psoriatic arthritis who is in clinical remisson?

Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?

Would you choose bimekizumab over other IL-17 inhibitors in patients with increased levels of disease related pain and poor functional status?

What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?

How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?

How would you manage axial stiffness without pain in an elderly gentleman with a distant history of HLA-B27+ axial and peripheral spondyloarthritis, now with SI joint fusion, no peripheral arthritis, normal inflammatory markers, and no response to TNF inhibition?

For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?

Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?

Copyright © 2025 theMednet
All Rights Reserved.